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Abstract
Tripodal peptide analogues were designed based on the phosphotyrosine binding pocket of the Src
SH2 domain and assayed for their ability to bind to fluorescein-labeled phosphopeptides.
Fluorescence polarization assays showed that a number of amphipathic linear peptide analogues
(LPAs), such as LPA4, bind to fluorescein-labeled GpYEEI (F-GpYEEI). LPA4 was evaluated for
potential application in cellular delivery of phosphopeptides. Fluorescence microimaging cellular
uptake studies with fluorescein-attached LPA4 (F-LPA4) alone or the mixture of LPA4 and F-
GpYEEI in BT-20 cells showed dramatic increase of the fluorescence intensity in cytosol of cells,
indicating that LPA4 can function as a delivery tool of F-GpYEEI across the cell membrane.
Fluorescent flow cytometry studies showed the cellular uptake of F-LPA4 in an energy-independent
pathway, and confirmed the cellular uptake of F-GpYEEI in the presence of LPA4. These studies
suggest that amphipathic tripodal peptide analogues, such as LPA4, can be used for cellular delivery
of phosphopeptides.
Keywords
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Introduction
Recently, several classes of cell-penetrating peptides have been introduced as potential
transporters of other compounds that have low bioavailability across cell membranes.1–5 For
example, arginine oligomers containing six or more amino acids, either alone or when
conjugated to therapeutic agents have been shown to cross readily a variety of cell types very
efficiently.6–22 In general, cell-penetrating peptides are polybasic (high guanidinium content),
20–24 hydrophobic,25 or amphipathic.4,26 These properties determine the mechanism of the
cellular uptake by these compounds.
Phosphopeptides have proven to be very valuable reagents for the study of protein
phosphorylation and dephosphorylation. These compounds have been used to probe substrate
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specificity of the Src homology 2 (SH2) domain,27 phosphotyrosine binding (PTB) domains,
28,29 and phosphatases30,31 in cell-free systems. Interactions between the negatively charged
phosphate group of phosphopeptides or phosphoproteins and positively charged amino acids
in binding pockets of a number of proteins have been demonstrated to be critical in several
protein-ligand or protein-protein interactions.32,33
Studies of phosphopeptides in cellular systems are complicated by the fact that in general
phosphopeptides do not readily cross cellular membranes due to poor transport of the
negatively charged phosphate moiety through cell membranes. Chemical methods have been
used for delivery of phosphopeptides34–36 by conjugating phosphopeptides to other carrier
peptides in a single sequence of fusion construct.37 The phosphopeptide is separated from the
carrier in the cellular environment of the cytoplasm. In all these examples, the phosphopeptides
were covalently attached to carrier peptides. This approach has the disadvantage of need for
the synthesis of the fusion conjugates. The conjugation method is costly because of coupling
inefficiency of reactions. Furthermore, the covalently bound fusion constructs must be cleaved
by a specific chemical or enzymatic reaction to release phosphopeptides upon the cellular
uptake.
Prompted by the potential broad value of using phosphopeptide in studying signaling pathways
in cellular environment, we initiated a program aimed to deliver negatively charged
phosphopeptides to cells by using tripodal positively charged peptides and without using a
covalent attachment. The structural features of tripodal positively charged peptides as carrier
molecules were designed based on the Src SH2 domain phosphotyrosine (pTyr) binding pocket.
pTyr-Glu-Glu-Ile (pYEEI) peptide template has been shown to be the optimal binding sequence
for the Src SH2 domain of the Src kinase.27,38 The crystal structure of pYEEI in complex
with the Src SH2 domain reveals that the pTyr residue is buried in the deep hydrophilic pTyr-
binding pocket,27 and interacts with three positively charged amino acids, Arg158, Arg178,
and Lys206 located in a triangle positions relative to pTyr, through a network of hydrogen
bonding and electrostatic interactions.
Based on this mode of interaction with three positively charged amino acids surrounding pTyr
residue of pYEEI within the Src SH2 domain binding pocket, a number of tripodal peptides
analogues were synthesized to elucidate whether they can have potential interactions with
phosphopeptides and/or can be used for their cellular delivery. The peptides were designed to
have at least three amino acids, including two Arg and one Lys residues, linked together through
a linker. The positively charged side chains of the amino acids possibly form a triangle structure
or create appropriate positioning for interactions with the negatively charged phosphopeptides.
These compounds included one cyclic peptide (CP), one dendrimer peptide analogue (DPA),
and nine linear peptide analogues (LPA1–LPA9) containing short and long linkers (Figure 1).
Short and long linkers in LPA analogues were used to determine the importance of spacing
between three positively charges side chains of amino acids for providing appropriate
interactions with the phosphopeptides. Fluorescent polarization assay was used to determine
the binding and/or aggregation of these analogues with phosphopeptides. The potential of
selected peptides for cellular delivery of phosphopeptides was investigated by using fluorescent
microimgaing and flow cytometry. To the best of our knowledge, this is the first report of using
a non-covalent approach for cellular delivery of phosphopeptides.
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Results and Discussion
Chemistry
All compounds were prepared by the solid-phase synthesis using standard N-(9-fluorenyl)
methoxycarbonyl (Fmoc)-based chemistry. Crude peptides were precipitated by addition of
cold diethyl ether (Et2O) and were purified by preparative reverse-phase HPLC. The chemical
structures of oligomeric compounds were determined by a high-resolution PE Biosystems
Mariner API time of flight electrospray mass spectrometer.
The cyclic peptide (CP) was synthesized (Scheme 1) by linking the three amino acid residues,
Arg, Arg, and Lys with a β-alanine linker. Acetyl chloride was reacted with trityl alcohol resin
(1, 0.61 mmol/g) swelled in dry toluene at 60 °C to afford trityl chloride resin (2). Resin 2 was
subjected to reaction with N-α-L-Fmoc-Glu(γ-OAll)-OH in dry DCM in the presence of N,N-
diisopropylethylamine (DIPEA) to yield 3. Fmoc peptide chemistry on resin-bound amino acid
3 was carried out using 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU) and N-methylmorpholine (NMM) as coupling and activating
reagents, respectively, piperidine (20% in DMF) as a deprotecting reagent, and N,N-
dimethylformamide (DMF) as a solvent. The amino acids used in the sequence were Fmoc-
Arg(Pbf)-OH, Fmoc-β -Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-β-Ala-OH, and Fmoc-Lys(Boc)-
OH, respectively, to yield 4. The allyl group was deprotected by treatment of 4 with CHCl3/
AcOH/NMM (37:2:1) and Pd(Ph3P)4 by mixing at room temperature for 3 h. The N-Fmoc
group was deprotected using piperidine in DMF for 10 min. The cyclization was carried out
by adding HBTU and DIPEA and mixing at room temperature for 16 h. The peptide was cleaved
from the resin using TFA/anisole/water (90:5:5) to afford CP.
The synthesis of DPA was started by branching from nitrogen containing Mmt group in (1N-
Dde, 8N-Mmt-spermidine-4-yl)-carbonyl Wang resin (5) (Scheme 2). All the chains were then
extended by using Fmoc peptide synthesis. For the deprotection of the Mmt group in 5 (0.43
mmol/g), the resin was suspended in a mixture of TFE/DCM (1:1). To the resulting suspension
was added HOBt. The mixing was continued for 3 h. The completely washed and dried resin
in dry DMF was subjected to reaction with N-α-Fmoc-Lys(Dde)-OH in the presence of HBTU
and DIPEA for 30 min at room temperature. The coupling reaction was repeated in another
cycle for 1 h to afford 6.
Fmoc deprotection of 6 was performed in the presence of piperidine in DMF (20%). The
coupling reaction with the second amino acid, FmocNH(CH2)4COOH, was carried out in the
presence of HBTU and DIPEA to produce 7. Fmoc deprotection and subsequent coupling
reaction with N-α-Fmoc-Lys(tBu)-OH in 7 afforded 8.
The deprotection of Dde groups in 8 was carried out by reaction with hydrazine monohydrate
in DMF (2%) for 2 min. Coupling reaction with N-α-Fmoc-Arg(Pbf)-OH using the condition
described above for coupling afforded 9. Fmoc deprotection, followed by cleavage from the
resin using TFA/DCM (50:50) produced DPA.
LPAs (Figure 1) were synthesized by the solid-phase Fmoc-based chemistry employing Fmoc-
Arg(pbf)-Wang resin (10) or Fmoc-Lys(Boc)-Wang resin as starting amino acids and Fmoc-
L-amino acid as building blocks. The synthesis of LPA8 is shown as a representative example
in Scheme 3 starting from Arg-attached Wang resin deptrotection, followed by coupling
reaction with FmocNH(CH2)11COOH, FmocNH(CH2)5COOH, Fmoc-Lys(Boc)-OH,
FmocNH(CH2)COOH, FmocNH(CH2)5COOH, and Fmoc-Arg(Pbf)-OH, respectively. HBTU
and NMM in DMF were used as coupling and activating reagents, respectively. Fmoc
deprotection at each step was carried out using piperidine in DMF (20%). A mixture of TFA/
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anisole/water (90:5:5) was used for side chain deprotection of amino acids and cleavage of the
synthesized peptide from the resin.
Phosphopeptides, such as GpYEEI, were labeled with 5(6)-carboxyfluorescein for fluorescent
polarization assays. The fluorescent probes were synthesized according to the previously
reported procedure.39,40 Fluorescein-labeled LPA4 (F-LPA4) was synthesized (Scheme 4)
by coupling of 5-carboxyfluorescein succinimidyl ester with a Wang resin-bound peptide
containing LPA-4 sequence and a glycine linker (12). Resin 12 and DIPEA were added to a
solution of 5-carboxyfluorescein succinimidyl ester in anhydrous DMF. The mixture was
shaken for 48 h at room temperature. The resin was cleaved using a solution of TFA/water/
triisopropylsilane (5.0 mL:0.5 mL:0.5 mL) for 2.5 h. The crude product was purified by
preparative reverse-phase HPLC. The chemical structure of F-LPA4 was determined by a high-
resolution electrospray time of flight electrospray mass spectrometer.
Binding of tripodal peptides to phosphopeptides
Figure 2 illustrates the comparative binding of all peptide analogues to a fluorescein-labeled
phosphopeptide probe, F-GpYEEI, using the fluorescence polarization (FP) assays according
to the previously reported procedure.39,40 The FP intensity reflects the local mobility of the
chromophore upon binding. The LPAs containing long linkers (LPA4–LPA9) showed dramatic
increase of the FP values, suggesting that these compounds form high molecular weight
complexes with less local mobility in the presence of F-GpYEEI. However, the LPAs
containing short linkers (LPA1–LPA3), CP, and DPA showed very low fluorescence
polarization values even at maximum peptide concentration (500 µM) in the presence of the
fluorescent probe.
The data in Figure 2 shows that the spacing between positively charged residues differentiates
the binding of tripodal peptide analogues to phosphopeptides. Peptides containing longer
linkers exhibited higher aggregation. The presence of the longer linkers appears to generate
appropriate positioning of positively charged groups for interaction with phosphopeptides.
Increased flexibility in the backbone could allow the positively charged head groups to interact
more effectively with the negative charges of phosphopeptides. LPA4–LPA9 containing long
chain hydrophobic linkers are more flexible than other compounds, and can form complexes
with themselves and the phosphopeptide probes through a combination of hydrophobic and
electrostatic interactions. On the other hand, CP, DPA, and LPA1–LPA3 have rigid structures
or short linkers that will not allow the three positively charged amino acid side chains, either
attached to the central backbone cyclic ring in CP or attached through short linkers in LPA1–
LPA3 and DPA, to create appropriate positioning of positively-charged groups for the
interactions with the negatively charged F-GpYEEI. LPA4–LPA9 did not show any significant
differences in generating maximum fluorescence polarization in the presence of F-GpYEEI,
suggesting approximately similar local mobility and/or size of formed aggregates.
The role of F-GpYEEI in the formation of complexes containing LPA4
To determine whether the presence of F-GpYEEI contributes in the formation of the complexes
with less local mobility or LPA4 can self-assemble to form such complexes in the absence of
F-GpYEEI, a fluorescent derivative of LPA4, F-LPA4, was synthesized using 5-
carboxyfluorescein succinimidyl ester and LPA4 as described above. Figure 3 displays the
results of incubation of different concentrations of LPA4 in the presence of F-GpYEEI (80
nM) or F-LPA4 (nM). These data showed the significant increase in the FP values of LPA4 +
F-GpYEEI when compared to those of LPA4 + F-LPA4. Thus, the presence of negatively
charged F-GpYEEI enhances the formation of high molecular weight complexes with less local
mobility possibly through intermolecular electrostatic interactions with positively charged
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residues in LPA4. These data show that the complexes are not formed exclusively by self-
assembly of LPA4.
The binding of LPAs containing long linkers with other phosphopeptides
To determine the structural requirements of phosphopeptides for the binding to the LPAs
containing long linkers, a series of fluorescently labeled analogues of phosphopeptides were
synthesized by using standard solid-phase chemistry as described above. LPA8 was assayed
against other fluorescent peptide probes with different sequences (e.g., F-AMpYSSV, F-
pYTKM, and F-pYTSM). Figure 4 (left) displays the results of incubation of different
concentrations of LPA8 with constant concentration of the fluorescent probes. The complex
between LPA8 and F-GpYEEI exhibited higher fluorescence when compared with that of other
fluorescein-labeled probes. The difference of the FP intensity of F-GpYEEI compared to the
other three probes indicated that the interactions are sequence dependent and LPA8 prefer
specific sequences for binding. The absence of glutamic acids in F-GpYTKM and F-GpYTSM
reduced the aggregation between these peptides and LPA8 when compared with that of F-
GpYEEI. Figure 4 (right) displays the results of incubation of a number of fluorescent probes
and control F-GpYEEI with LPA4. Replacement of the glutamic acids in F-GpYEEI with
alanine residues in F-GpYAAI reduced the FP values. Furthermore, LPA4 did not interact
significantly with F-LPA4 alone. Therefore, in addition to the phosphate group, the carboxylic
acid side chains of glutamic acid in F-GpYEEI are contributing in the selectivity and aggregate
formation, possibly through electrostatic interactions with positively charged groups in LPA4
or LPA8. We selected F-GpYEEI for further cellular uptake studies, because of its higher
aggregation with LPA analogues and its importance in interaction with the Src SH2 domain.
27,38
Cellular Uptake Studies
The most common methods to study internalization of cell-penetrating peptides have been to
visualize uptake by fluorescence microscopy and to measure it quantitatively by fluorescence-
activated cell sorter (FACS) analysis. Fluorescence microimaging and flow cytometry were
used to determine the potential of the tripodal LPAs containing long hydrophobic linkers and
arginine-lysine residues as molecular transporters or delivery tools of phosphopeptides into
cells.
Cellular uptake of F-LPA4
Fluorescein-conjugated peptide, F-LPA4, was incubated with the BT-20 cells. A dramatic
increase of the fluorescence intensity was observed in a time-dependent manner in cytosol of
the cells, suggesting that the F-LPA4 can cross the cell membrane. Additionally, a cellular
uptake assay was carried out using different concentrations of F-LPA4 (5–100 µM), suggesting
that the fluorescence intensity and therefore the cellular uptake of this compound were
concentration-dependent (Figure 5).
Cellular uptake of F-GpYEEI in the presence of LPA4
Cellular uptake assay was carried out using MDA-MB-468 cells. Cellular uptake studies of F-
GpYEEI were carried out in the presence and absence of LPA4. Figure 6 shows when only the
F-GpYEEI was incubated with the cells, the fluorescence intensity remains low even after 30
min incubation possibly because negatively charged F-GpYEEI cannot cross the cell
membrane significantly. In the presence of LPA4 under similar conditions, a dramatic increase
in the fluorescence intensity inside the cells was observed, suggesting that tripodal peptide
LPA-4 can function as a delivery tool of F-GpYEEI across the cell membrane possibly by
encapsulation of the probe. These data were consistent with the previous assay using BT-20
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cells, suggesting that LPA4 may be used as a transporter of negatively charged compounds
like GpYEEI into cells.
Similarly, real time fluorescence microscopy after incubation of live BT-20 cells for 30 min
with F-GpYEEI (10 µM) and LPA4 (50 µM) showed dramatic increase in the fluorescence
intensity inside the cells (Figure 7). Similar experiments using the control (no compound), F-
GpYEEI alone, F-GpYEEI + LPA1 did not show any significant intracellular fluorescence.
Cell viability assay
BT-20 cell viability was assayed using Vi-Cell Cell Viability Analyzer (Beckman Coulter).
The results are presented in Figure 8. Cells were viable >96%, suggesting that F-GpYEEI, F-
LPA4, F-GpYEEI + LPA1 and F-GpYEEI + LPA4 were not cytotoxic after incubation under
experimental conditions used for the cellular assays. Cell viability assay indicated that cells
were not killed in the presence of different analogues; therefore, the cell penetration was not
due to cell death.
Flow cytometry studies
The ability of these fluorescently labeled peptides to enter cells was then analyzed and the
intracellular fluorescence was quantified using flow cytometry.
FACS analysis of F-LPA4
The ability of LPA4 to penetrate cells was tested by incubating fluorescein-labeled LPA4 with
BT-20 cells (Figure 9). Fluorescein conjugate of LPA4 rapidly entered at each of the
concentrations analyzed. The study showed a concentration-dependent pattern for cellular
uptake of F-LPA4. Sodium azide inhibits energy-dependent cellular uptake.41 Endocytic
cellular uptake is the major mechanism for some of the cell-penetrating peptides.3 The addition
of sodium azide at high concentration of 77 mM did not inhibit internalization of F-LPA4
(Figure 9). Therefore, the cellular uptake of F-LPA4 is not ATP dependent as it occurred in
cells depleted of ATP. The mechanism of cellular uptake remains unclear. The distribution of
basic and hydrophobic residues suggests that LPA4 is partly amphipathic. The amphipathic
nature of the compound may be an important factor in the cellular uptake. The mechanism of
cellular uptake for amphipathic peptides have been previously proposed.42 Most
biomembranes are neutral at the outer surface and negative inside because of the presence of
phospholipids bilayer. The translocation of the amphipathic peptide LPA4 through the plasma
membrane is mediated possibly by interactions with the membrane lipids. These peptides have
large hydrophobic spacers that are membrane-permeable. There is an inner hydrophobic layer
between two outer hydrophilic surfaces in the membranes of cells. The cationic residues in
LPA4 are required to improve the complex formation with hydrophilic negatively charged
residues in the membrane. Cationic residues of LPA4 interact with negatively charged
phospholipids in the plasma membrane. Arginine and lysine remain positively charged and are
able to exert electrostatic binding. Subsequent interaction of the hydrophobic residues between
LPA4 and the hydrophobic residues in membrane probably induces an encapsulation of LPA4
in the plasma membrane. After perturbation of lipid bilayer and reorganization of lipids, the
peptide is released intracellularly.
Surprisingly in the presence of sodium azide, the cellular uptake was slightly higher at all tested
concentrations when compared with that of in the absence of sodium azide. The mechanism
of this observation is unknown, but could be due to reducing the electrostatic repulsion between
positively charged residues in LPA4 and promoting interchain hydrophobic interactions,
allowing more compounds to get into the cells. The observed increase of uptake was similar
to that seen when the ionic strength was increased and cells were pretreated with other salts,
such as Na2HPO4, KCl, and NaCl as shown later.
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Cellular uptake of F-GpYEEI in the presence of LPA4
To further evaluate tripodal peptide transporters as potential agents for cell delivery, we sought
to determine whether these agents could transport a phosphopeptide into the cells. The ability
of LPA4 to enable cellular uptake of F-GpYEEI was determined by FACS analysis in BT-20
cells with an incubation time of 30 min at 37 °C. In this assay, F-GpYEEI displayed very
limited cellular uptake when used alone (Figure 10).
As described above LPA1 is a peptide that showed weak binding and aggregation with
phosphopeptides based on fluorescence polarization assays (see Figure 3). Therefore, LPA1
was used as a negative control in cellular uptake assays. In the presence of LPA1, there was
no significant improvement in the cellular uptake of F-GpYEEI. In striking contrast, in the
presence of LPA4 there was approximately 10-fold higher cellular uptake of F-GpYEEI when
compared with that of F-GpYEEI alone (Figure 10). The amphipathic nature of the tripodal
peptide analogue appears to be essential in the molecular transporter property. LPA1 did not
efficiently translocate F-GpYEEI into cells. Therefore, the presence of several positively
charged moieties on a molecular scaffold is not the only required structural element for
molecular transporter property. The length of the linkers had a dramatic effect on aggregation.
The cellular uptake of F-GpYEEI was improved by increasing the number of spacer units
between positively charged groups in the molecular transporter as shown in LPA4 when
compared with that of LPA1. Thus, in addition to the positively charged groups, the
hydrophobicity and/or conformational mobility of designed transporters also plays a role in
cellular uptake. These results are consistent with binding data between LPA analogues and F-
GpYEEI. By increasing hydrophobicity and/or the conformational freedom of the backbone
of peptides through addition of longer linkers, a significant enhancement in the binding of
LPAs to F-GpYEEI was seen (Figure 2).
Furthermore, when fluorescein-labeled GYEEI, a control peptide without the phosphate group,
was used, there was no cellular uptake in the presence or absence of tripodal peptides, LPA1
and LPA4 (Figure 10). These data indicate the cellular uptake of F-GpYEEI by LPA4 also
requires electrostatic interactions between negatively charged phosphate in the cargo and the
positively charged functional group on the tripodal peptide. In general, the amphipathic
property of the tripodal peptide is essential for cellular delivery of the phosphopeptides.
The results on fixed cells and FACS analysis were not based on artificial uptake of peptides
and false results. First, in addition to repeated washing steps preceding FACS analysis, trypsin
was added to remove peptides associated with the plasma membrane. This step prevents false
results associated with fixed cells in flow cytometry. Trypsin treatment is a known procedure
to eliminate any false reports.3,43 Second, control experiments such as using LPA1 and F-
GYEEI were used. There was no cellular uptake using these compounds, confirming the
cellular uptake is only selective for F-GpYEEI in the presence of LPA4. Finally, the cellular
uptake of F-LPA4 in the live BT-20 cells was concentration dependent (see Figure S1 in
Supporting Information). Furthermore, the cellular uptake assays with F-GpYEEI, F-
GpYTKM, and F-AMpYSSV were carried out in the presence and absence of LPA1 and LPA4
in live BT-20 cells (see Figure S2 in Supporting Information). The results were consistent with
the results in the trypsinized fixed cells. LPA4 was able to deliver F-GpYEEI 5-fold higher
when compared to those of F-GpYTKM and F-AMpYSSV. These data suggest the selective
cellular uptake of F-GpYEEI in the presence of LPA4. Therefore, fixing was not causing any
false results in our experiments, since the control compounds under similar conditions did not
show any uptake and similar experiments in live cells showed consistent results.
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Conformational analysis of LPA4 in the presence and absence of F-GpYEEI
To provide a better insight about the secondary structures of LPA4 and LPA4-phosphopeptide
conjugate, a conformational study based on circular dichroism (CD) was performed.
Amphipathicity of LPA4 may depend on the conformation of the peptide, with probably all
cationic residues pointing to one direction and the hydrophobic residues on the opposite side;
therefore, an ordered secondary structure is expected. Indeed, LPA4 adopted an ordered
secondary structure, presumably because of self-association. The CD spectrum of LPA4 is
characterized by a single minimum lying at 210 nm, indicative of the existence of a partly β
structure. The peptide showed a concentration-dependent CD spectrum (Figure 11a).
Upon the addition of F-GpYEEI (>10 µM) to the constant concentration of LPA4 (50 µM),
the CD spectrum was blue shifted (Figure 11b). For example with F-GpYEEI at 20 µM, the
position of minimum is centered near 203 nm that is lower than that for peptides in pure β-
sheet structures (217 nm). All spectra were corrected for background by subtraction of
appropriate blanks, such as F-GpYEEI alone. These results suggest that the charge interactions
of LPA4 with F-GpYEEI induce formation of a mixture of various structures possibly by
encapsulation of phosphopeptide by the tripodal peptide. These structures still maintain an
ordered secondary structure with the conformations partly based on a β-sheet conformation.
The effect of ionic strength on cellular uptake of F-GpYEEI in the presence of LPA4
The precise mechanism of LPA4 cellular delivery system remains unknown. The amphipathic
property of LPA4 appears to play an important role in transporting F-GpYEEI into cells. Based
on the several control experiments explained above, a combination of electrostatic and
hydrophobic interactions is required for successful cellular uptake by LPA4. To provide better
insights about the mechanism of cellular uptake, the experiments were carried out by
modifications of the medium. To test whether the ionic strength was a factor in transport of
cation-rich transporters, fluorescently labeled peptide was incubated with the cells for 30 min
in the presence of different salt solutions, NaCl (138 mM), KCl (141 mM), and Na2HPO4 (0.05
mM or 0.1 mM). The cells were washed and analyzed by flow cytometry. When the assay was
carried out in the presence of salt ions, the cellular uptake was increased by 3–6 fold (Figure
12). The mechanism of this observation is unknown. It is generally assumed that salt reduces
the electrostatic repulsion between positive charges, and promotes interchain hydrophobic
interactions. The hydrophobic residues become better packed into stronger networks in ionic
solutions. It seems plausible that the addition of salt relaxes the electrostatic repulsions to allow
better assembly of the hydrophobic network presumably because of self-association of
hydrophobic faces of the amphipathic peptide. Thus, increasing the ionic strength enhanced
the cellular uptake probably by enhancing the hydrophobic interactions between amphipathic
peptides and cell membrane and reducing electrostatic repulsion between positive charges in
LPA4. The ion pair complex of LPA4 and F-GpYEEI partitions into the lipid bilayer and
migrate across by passive diffusion. The complex dissociates on the inner side of the membrane
and the transporter and cargo enter the cytosol. Furthermore, salt ions may disrupt electrostatic
interactions between negatively charged phospholipids in the membrane and positively
charged residues in LPA4, allowing more tripodal peptide along with its cargo to get into the
cells. Further studies are required to determine the mechanism of ionic strength on cellular
uptake of F-GpYEEI.
Cellular uptake of d(TTTTTTTTTTTT) by LPA4
To further investigate whether LPA4 can act as molecular transporter of other negatively
charged molecules such as oligonucleotides, 5'-fluorescence-labeled d(TTTTTTTTTTTT) was
incubated with the BT-20 cells in the presence and absence of peptides. Cellular uptake studies
using LPA4 and a fluorescein-labeled 12-mer thymidine oligonucleotide showed only two-
fold improvement in cellular delivery. Although the flow cytometry studies showed a slightly
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higher uptake in the presence of LPA4 than that of in the absence of LPA4 (Figure 13), the
difference was not dramatic when compared with the similar studies in the presence of F-
GpYEEI. Therefore, LPA4 does not appear to be a suitable carrier for transporting the
oligonucleotide across the cell membrane.
Conclusions
We report the synthesis and evaluation of tripodal molecular transporters, which combine both
the cationic and the lipophilic properties. Some of the tripodal peptides showed amphipathic
properties. The binding of several tripodal peptides to phosphopeptide probes was evaluated
using FP assays. In general, an increase in spacing between three positively charged amino
acids in peptides led to an increase in binding and aggregation with F-GpYEEI. LPAs
containing long chain hydrophobic linkers exhibited high FP intensity in the presence of
specific phosphopeptides, suggesting the formation of complexes with less local mobility
through combination of hydrophobic and electrostatic interactions. Fluorescently labeled
tripodal peptide F-LPA4 was evaluated for their cellular uptake studies. The cellular uptake of
F-LPA4 was not inhibited with high concentrations of sodium azide, an inhibitor of ATP-
mediated uptake, suggesting that the delivery of phosphopeptides by LPA-4 was not energy
dependent. LPA4 was found to be an efficient molecular transporter of F-GpYEEI into the
cells. Long, hydrophobic, and/or flexible spacing in the tripodal positively charged peptide
resulted in the most effective transport into cells exceeding that of phosphopeptides. Cellular
uptake studies suggested the potential of these compounds for the cellular delivery of
phosphopeptides. Cellular internalization via these peptides do not need prior chemically
covalent coupling. Further optimization of the peptides may provide specific molecular
transporters for different phosphopeptides.
Experimental Section
1. General Information
All reactions were carried out in Bio-Rad polypropylene columns by shaking and mixing using
a Glass-Col small tube rotator in dry conditions or on a PS3 automated peptide synthesizer
(Rainin Instrument Co., Inc.) at room temperature unless otherwise stated. In general, all
peptides were synthesized by the solid-phase synthesis strategy employing Fmoc-based
chemistry and Fmoc- Fmoc-L-amino acid building blocks. HBTU and NMM in DMF were
used as coupling and activating reagents, respectively. Fmoc-amino acid-Wang resins, trityl
alcohol resin, (1N-Dde, 8NMmt-spermidine-4-yl)-carbonyl Wang resin, coupling reagents, and
Fmoc-amino acid building blocks were purchased from Novabiochem. Other chemicals and
reagents were purchased from Sigma-Aldrich Chemical Company (Milwaukee, WI, USA).
Fmoc deprotection at each step was carried out using piperidine in DMF (20%). A mixture of
TFA/anisole/water (90:5:5) or TFA/DCM (50:50) was used for side chain deprotection of
amino acids and cleavage of the synthesized peptides from the resin. Crude peptides were
precipitated by addition of cold diethyl ether (Et2O), and were purified by preparative reverse-
phase HPLC. The chemical structures of compounds were determined by a high-resolution PE
Biosystems Mariner API time of flight electrospray mass spectrometer. 5'-Fluorescence-
labeled d(TTTTTTTTTTTT) was purchased from Integrated DNA Technologies, Inc. and was
desalted and purified.
2. Chemistry
2.1. Synthesis of Cyclic Peptide (CP)—Trityl alcohol resin (1, 165 mg, 0.1 mmol, 0.61
mmol/g) was swelled in dry toluene (5 mL) for 10 min. Acetyl chloride (552 mg, 0.5 mL, 7.0
mmol) was added dropwise to the swelled resin. The mixture was heated at 60 °C for 3 h. The
solvents were drained and the resin was washed thoroughly with dry DCM (50 mL) to afford
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trityl chloride resin (2). Resin 2 was suspended in dry DCM (5 mL). N-α-L-Fmoc-Glu(γ-OAll)-
OH (100 mg, 0.25 mmol) was added in one portion, followed by DIPEA (150 µL, 1.1 mmol)
to the suspension. The resulting mixture was mixed for 1.5 h at room temperature and the
solvent was drained. The resin was washed extensively with MeOH (50 mL) and DCM (50
mL), and dried overnight under vacuum to yield 3. Resin 3 was subjected to Fmoc peptide
chemistry as described above. The amino acids used in the sequence were Fmoc-Arg(Pbf)-OH,
Fmoc-β-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-β-Ala-OH, and Fmoc-Lys(Boc)-OH,
respectively, to yield 4. The allyl group in 4 was deprotected by treatment with Pd(Ph3P)4/
CHCl3/AcOH/NMM. Briefly, the resin was suspended in a mixture of CHCl3/AcOH/NMM
(37:2:1, 5 mL). Pd(Ph3P)4 (360 mg, 0.32 mmol) was added to the resulting suspension. The
mixture was mixed for 3 h at room temperature and the resin was washed extensively with
DMF (50 mL), MeOH (50 mL), and DCM (50 mL), respectively. The N-terminal was
deprotected using piperidine in DMF (20%, 5 mL) for 10 min. The resin was washed with
DMF (50 mL), MeOH (50 mL), and DCM (50 mL), respectively, dried completely, and then
suspended in dry DMF (5 mL). The cyclization was carried out by adding HBTU (300 mg, 0.8
mmol) and DIPEA (300 µL). The mixture was mixed for 16 h at room temperature. The peptide
was cleaved from the resin using TFA/anisole/water (90:5:5, 5 mL) and precipitated using cold
ether and purified by HPLC to yield CP.
1H NMR (D2O, 400 MHz, δ ppm): 4.48-4.38 (m, CHα, 1H), 4.38-4.10 (m, CHα, 2H), 4.04-3.94
(m, CHα, 1H), 3.60-3.34 (m, 5H), 3.28-3.10 (m, 5H), 3.10-2.76 (m, CH2NH, 10H), 2.60-2.36
(m, CH2CO, 6H), 1.85-1.28 (m, CH2, 14H); HR-MS (ESI-TOF) (m/z): C29H53N13O8, calcd,
711.4297; found, 711.6298 [M]+, 712.6330 [M + H]+, 356.9862 [M + H]+2, 238.6754 [M +
H]+3.
2.2. The Synthesis of Dendrimer Peptide Analogue (DPA)—(1N-Dde, 8N-Mmt-
spermidine-4-yl)-carbonyl Wang resin (233 mg, 0.1 mmol, 0.43 mmol/g) was suspended in
DMF (5 mL) and was shaken for 10 min. The solvent was drained and the resin was suspended
again in DMF (5 mL) and shaken for additional 10 min. The resin was then washed with DMF
(20 mL), MeOH (20 mL) and DCM (20 mL), respectively. For the deprotection of the Mmt
group in 5, the resin was suspended in a mixture of TFE/DCM (5 mL, 1:1). HOBt (76 mg, 0.56
mmol) was added to the resulting suspension. The mixing was continued for 3 h. The solvent
was drained and the process was repeated once. The resin was washed extensively with DMF
(20 mL), MeOH (20 mL), and DCM (20 mL), respectively, and was dried completely under
vacuum for the next step. The completely washed and dried resin was suspended in dry DMF
(5 mL), to which N-α-Fmoc-Lys(Dde)-OH (0.2 mmol, 2 eq), HBTU (76 mg, 0.2 mmol), and
DIPEA (150 µL, 1.1 mmol) were added. The resulting suspension was mixed for 30 min at
room temperature. The solvent was drained and the resin was washed with DMF (20 mL). The
coupling was repeated in another cycle for 1 h. The resin was washed thoroughly using DMF
(20 mL), MeOH (20 mL), and DCM (20 mL), respectively, and dried under vacuum overnight
to afford 6. Resin 6 was suspended in piperidine in DMF (5 mL, 20%) and the suspension was
mixed for 10 min to deprotect the Fmoc group. The solvent was drained and the process was
repeated once. The resin was washed extensively with DMF (20 mL), MeOH (20 mL), and
DCM (20 mL), respectively. The resin was dried completely under vacuum for the next step.
The coupling reaction with the second amino acid, FmocNH(CH2)4COOH was carried out
using the conditions described above for Fmoc peptide synthesis to produce 7. Fmoc
deprotection and coupling with N-α-Fmoc-Lys(tBu)-OH in 7 afforded 8. Resin 8 was
suspended in hydrazine monohydrate in DMF (5 mL, 2%) and the suspension was mixed for
2 min to deprotect the Dde group. The solvent was drained and the process was repeated once.
The resin was washed extensively with DMF (20 mL), MeOH (20 mL), and DCM (20 mL),
respectively, and dried completely under vacuum. Coupling reaction with N-α-Fmoc-Arg(Pbf)-
OH using the conditions described above for Fmoc peptide synthesis afforded 9. Fmoc group
Ye et al. Page 10
J Med Chem. Author manuscript; available in PMC 2008 September 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
was deprotected as described above. The peptide was cleaved from the resin using TFA/DCM
(50:50), precipitated using cold ether, and purified by HPLC to yield DPA.
1H NMR (D2O, 400 MHz, δ ppm): 4.23 (t, J = 8.00, CHα Arg, 1H), 4.09 (t, J = 8.00 Hz,
CHα Arg, 1H), 4.02 (t, CHα Lys, J = 8.00 Hz, 1H), 3.97-3.88 (m, CHα Lys, 2H), 3.39-3.09
(m, CH2NH, 12H), 3.06-3.00 (m, CH2NH, 4H), 2.95 (t, J = 8.00 Hz, CH2NH, 2H), 2.32-2.24
(m, CH2CO, 2H), 2.00-1.82 (m, 8H), 1.78-1.24 (m, CH2, 26H); HR-MS (ESI-TOF) (m/z):
C36H76N16O5, calcd, 812.6185; found, 429.431 [C19H43N9O2]2+, 407.9538 [M + 2H]2+,
329.9330 [C15H33N6O2]2+.
2.3. General Procedure for the Synthesis of LPAs—LPAs were synthesized by the
solid-phase Fmoc-based chemistry using Fmoc-Arg(pbf)-Wang resin or Fmoc-Lys(Boc)-
Wang resin as starting amino acids. Fmoc-L-amino acid building blocks included FmocNH
(CH2)11COOH, FmocNH(CH2)4COOH, FmocNH(CH2)5COOH, Fmoc-Lys(Boc)-OH, and
Fmoc-Arg(Pbf)-OH. HBTU and NMM in N,N-dimethylformamide (DMF) were used as
coupling and activating reagents, respectively. Fmoc deprotection at each step was carried out
by using piperidine in DMF (20%). A mixture of TFA/anisole/water (90:5:5) was used for side
chain deprotection of amino acids and cleavage of the synthesized peptides from the resin.
Crude peptides were precipitated by addition of cold diethyl ether (Et2O) and purified by
reverse phase HPLC. The synthesis of LPA8 is shown as a representative example in Scheme
3 starting from Arg-attached Wang resin. The chemical structures of compounds were
determined by a high-resolution electrospray time of flight electrospray mass spectrometer.
LPA1: 1H NMR (D2O, 400 MHz, δ ppm): 4.34-4.24 (m, CHα Arg, 1H), 4.08 (t, J = 8.00 Hz,
CHα Arg, 1H), 3.88 (t, J = 8.00 Hz, CHα Lys, 1H), 3.30-3.06 (m, CH2NH, 8H), 2.91 (t, J =
8.00 Hz, CH2NH, 2H), 2.32-2.18 (m, CH2CO, 4H), 1.92-1.80 (m, 3H), 1.76-1.26 (m, CH2,
20H); HR-MS (ESI-TOF) (m/z): [C28H56N12O6] calcd, 656.4446; found, 656.8206 [M]+,
657.8174 [M + H]+, 329.5605 [M + H]+2, 220.3718 [M + H]+3.
LPA2: 1H NMR (D2O, 400 MHz, δ ppm): 4.34-4.26 (m, CHα Arg, 1H), 4.11 (t, J = 8.00 Hz,
CHα Arg, 1H), 3.86 (t, J =8.00 Hz, CHα Lys 1H), 3.26-3.06 (m, CH2NH, 8H), 2.92 (t, J = 8.00
Hz, CH2NH, 2H), 2.34-2.20 (m, CH2CO, 4H), 1.94-1.80 (m, 3H), 1.76-1.30 (m, CH2, 20H);
HR-MS (ESI-TOF) (m/z): [C28H56N12O6] calcd, 656.4446; found, 656.8410 [M]+, 657.8492
[M + H]+, 658.8268 [M + 2H]+, 329.5687 [M + H]+2, 220.3805 [M + H]+3.
LPA3: 1H NMR (D2O, 400 MHz, δ ppm): 4.30-4.20 (m, CHα Arg, 2H), 3.97-3.90 (m, CHα
Lys, 1H), 3.32-3.02 (m, CH2NH, 8H), 2.93 (t, J = 8.00 Hz, CH2NH, 2H), 2.32-2.17 (m,
CH2CO, 4H), 1.92-1.80 (m, 3H), 1.78-1.30 (m, CH2, 20H); HR-MS (ESI-TOF) (m/z):
[C28H56N12O6] calcd, 656.4446; found, 656.8931 [M]+, 657.9010 [M + H]+, 658.9078 [M +
2H]+, 329.5875 [M + H]+2, 220.3914 [M + H]+3.
LPA4: 1H NMR (D2O, 400 MHz, δ ppm): 4.31-4.19 (m, CHα Arg, 2H), 3.94-3.88 (m, CHα
Lys, 1H), 3.24-3.04 (m, CH2NH, 8H), 2.93 (t, J = 8.00 Hz, CH2NH, 2H), 2.30-2.18 (m,
CH2CO, 4H), 1.92-1.80 (m, 3H), 1.78-1.30 (m, CH2, 20H), 1.30-1.10 (m, CH2, 28H); HR-MS
(ESI-TOF) (m/z): [C42H84N12O6] calcd, 852.6637; found, 852.4374 [M]+, 853.4413 [M +
H]+, 854.4363 [M + 2H]+, 427.4579 [M + H]+2, 285.6866 [M + H]+3.
LPA5: 1H NMR (D2O, 400 MHz, δ ppm): 4.34-4.24 (m, CHα Arg, 1H), 4.16 (t, J = 8.00 Hz,
CHα Arg, 1H), 3.90 (t, J = 8.00 Hz, CHα Lys, 1H), 3.26-3.00 (m, CH2NH, 8H), 2.96-2.86 (m,
CH2NH, 2H), 2.34-2.16 (m, CH2CO, 4H), 1.96-1.80 (m, 3H), 1.76-1.34 (m, CH2, 20H),
1.30-1.10 (m, CH2, 28H); HRMS (ESI-TOF) (m/z): [C42H84N12O6] calcd, 852.6637; found,
852.4181 [M]+, 853.4208 [M + H]+, 854.9599 [M + 2H]+, 427.4429 [M + H]+2, 285.6863 [M
+ H]+3.
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LPA6: 1H NMR (D2O, 400 MHz, δ ppm): 4.36-4.26 (m, CHα Arg, 1H), 4.18 (t, J = 8.00 Hz,
CHα Arg, 1H), 3.92 (t, J = 8.00 Hz, CHα Lys, 1H), 3.32-3.04 (m, CH2NH, 8H), 3.00-2.86 (m,
CH2NH, 2H), 2.32-2.16 (m, CH2CO, 4H), 1.94-1.80 (m, 3H), 1.78-1.30 (m, CH2, 20H),
1.30-1.13 (m, CH2, 28H); HR-MS (ESI-TOF) (m/z): [C42H84N12O6] calcd, 852.6637; found,
852.4475 [M]+, 853.4585 [M + H]+, 854.4402 [M + 2H]+, 427.4549 [M + H]+2, 285.6664 [M
+ H]+3.
LPA7: 1H NMR (D2O, 400 MHz, δ ppm): 4.33-4.25 (m, CHα Arg, 1H), 4.25-4.15 (m, CHα
Arg, 1H), 3.89 (t, J = 8.00 Hz, CHα Lys, 1H), 3.25-3.00 (m, CH2NH, 12H), 2.95-2.85 (m,
CH2NH, 2H), 2.30-2.17 (m, CH2CO, 4H), 2.17-2.10 (m, CH2CO, 4H), 1.90-1.80 (m, 3H),
1.75-1.30 (m, CH2, 28H), 1.30-1.03 (m, CH2, 32H); HR-MS (ESI-TOF) (m/z):
[C54H106N14O8] calcd, 1078.8318; found, 1078.8075 [M]+, 540.2233 [M + H]+2, 360.8998
[M + H]+3.
LPA8: 1H NMR (D2O, 400 MHz, δ ppm): 4.31-4.24 (m, CHα Arg, 1H), 4.18-4.10 (m, CHα
Arg, 1H), 3.89 (t, J = 8.00 Hz, CHα Lys, 1H), 3.28-3.01 (m, CH2NH, 12H), 2.96-2.86 (m,
CH2NH, 2H), 2.30-2.06 (m, CH2CO, 8H), 1.92-1.80 (m, 3H), 1.78-1.32 (m, CH2, 28H),
1.30-1.05 (m, CH2, 32H); HR-MS (ESI-TOF) (m/z): [C54H106N14O8] calcd, 1078.8318; found,
1078.8078 [M]+, 540.2269 [M + H]+2, 360.9058 [M + H]+3.
LPA9: 1H NMR (D2O, 400 MHz, δ ppm): 4.28-4.21 (m, CHα Arg, 1H), 4.20-4.14 (m, CHα
Arg, 1H), 3.90 ((t, J = 8.00 Hz, CHα Lys, 1H), 3.28-3.02 (m, CH2NH, 12H), 2.98-2.88 (m,
CH2NH, 2H), 2.28-2.08 (m, CH2CO, 8H), 1.90-1.80 (m, 3H), 1.80-1.32 (m, CH2, 28H),
1.30-1.00 (m, CH2, 32H); HR-MS (ESI-TOF) (m/z): [C54H106N14O8] calcd, 1078.6103; found,
1078.8078 [M]+, 540.1669 [M + H]+2, 360.8712 [M + H]+3.
2.4. Synthesis of the Fluorescent Peptide Probes
2.4.1. 5-Carboxyfluorescein Succinimidyl Ester: To a solution of 5-carboxyfluorescein (150
mg, 0.40 mmol) in anhydrous DMF (1.5 mL) was added 1-[3-(dimethylamino)propyl]-3-
ethylcarbodiimide hydrochloride (EDAC; 93.6 mg, 0.49 mmol) followed by N-
hydroxysuccinimide (HOSu; 57.4 mg, 0.50 mmol). The flask was covered with foil and the
solution stirred under nitrogen for 4.5 h. After 4.5 h, additional EDAC (15.6 mg, 0.08 mmol)
was added and the reaction stirred under nitrogen overnight. The reaction mixture was rinsed
into a separatory funnel with a minimal amount of DMF and diluted with acetone (6.0 mL).
K-phosphate buffer (0.1 M, pH 6, 7.5 mL) was added and the mixture was extracted with
Et2O/ethyl acetate (EtOAc) (2:1, 9.0 mL). The organic layer was separated and the aqueous
layer extracted two times with Et2O/EtOAc (2:1, 7.5 mL). The combined organic extracts were
washed with water (3 × 6.0 mL) and brine (1 × 7.5 mL), respectively, dried over Na2SO4, and
filtered. The organic solvents were removed in vacuo. A residue was dissolved in 2.0 mL
acetonitrile and purified by HPLC. The spectroscopic data were identical with those reported
in literature.40
2.4.2. Coupling Reaction of the Peptide-Attached Resins with 5-Carboxyfluorescein
Succinimidyl Ester: The fluorescent probes were synthesized according to the previously
reported procedure.39,40 In summary, the peptide-attached resins and DIPEA (850 µL, 6.1
mmol) were added to a solution of 5-carboxyfluorescein succinimidyl ester (250 mg, 0.53
mmol) in anhydrous DMF (5.0 mL). The mixtures were stirred for 48 h at room temperature.
The resins were filtered, washed with DMF (100 mL), and cleaved using a solution of TFA/
water/triisopropyl silane (5.0 mL:0.5 mL:0.5 mL) for 2.5 h. The filtrates were collected,
concentrated, precipitated from cold ether, and the crude products were purified by preparative
reverse-phase HPLC. F-GpYEEI has been synthesized previously.39,40 The compounds were
characterized by a high-resolution electrospray time of flight electrospray mass spectrometer.
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HR-MS (ESI-TOF) (m/z): Fluorescein-Ala-Met-pTyr-Ser-Ser-Val (F-AMpYSSV)
C49H55N6O19PS calcd, 1094.2980; found, 1095.5000 [M + 1]+, 736.4097 [M –
fluorescein]+; Fluorescein-pTyr-Thr-Lys-Met (F-GpYTKM) C47H53N6O17PS calcd,
1036.2926; found, 1035.3250 [M − 1]+, 621.7533 [M- fluorescein -G]+; Fluorescein-pTyr-
Thr-Ser-Met (F-GpYTSM) C44H46N5O18PS calcd, 995.5572; found, 995.2296 [M]+;
Fluorescein-Gly-pSer-Glu-Glu-Ile (FGpSEEI) C42H46N5O20P calcd, 971.2474; found,
970.5358 [M − 1]+, 613.7610 [M - fluorescein]+, 387.1952 [M – fluorescein - GpS]+;
Fluorescein-Gly-Tyr-Glu-Glu-Ile (F-GYEEI) C48H49N5O17 calcd, 967.3124; found,
968.6399 [M + 1]+, 609.8211 [M – fluorescein]+, 387.1941 [M – fluorescein - GY]+; and
Fluorescein-Gly-pTyr-Ala-Ala-Ile (F-GpYAAI) C44H46N5O16P calcd, 931.26772; found,
930.7029 [M]+.
2.5. Synthesis of F-LPA4—The fluorescent probe was synthesized by coupling of 5-
carboxyfluorescein succinimidyl ester with a Wang resin-bound peptide containing the LPA-4
sequence and a glycine linker (12). Resin 12 (0.1 mmol) and DIPEA (850 µl, 6.1 mmol) were
added to a solution of 5-carboxyfluorescein succinimidyl ester (250 mg, 0.53 mmol) in
anhydrous DMF (5.0 mL). The mixture was stirred for 48 h at room temperature. The resin
was filtered, washed with DMF (100 mL), and cleaved using a solution of TFA/water/
triisopropyl silane (5.0 mL:0.5 mL:0.5 mL) for 2.5 h. The filtrate was collected, concentrated,
precipitated from cold ether, and the crude product was purified by preparative reverse-phase
HPLC. The chemical structure of F-LP4 was determined by a high-resolution electrospray time
of flight electrospray mass spectrometer. HR-MS (ESI-TOF) (m/z): F-LPA4 C65H97N13O13
calcd, 1267.7329, found, 1265.8769 [M - 2H]+, 634.3520 [M]2+, 423.6989 [M + H]3+.
3. Binding Assays
Binding assays against the fluorescent probes were carried out using a fluorescent polarization
(FP) assay. FP intensities were measured at 25 °C in a disposable glass tube (volume 600 µL)
using a Perkin Elmer LS 55 luminescence spectrometer equipped with an FP apparatus. The
excitation and emission wavelengths were set at 485 and 535 nm, respectively. For the assays,
final concentrations of 80 nM fluorescent probe, phosphate buffer (20 mM, pH 7.3, 100 mM
NaCl, 2 mM DTT, 0.1% BSA), water, and various concentrations (0–0.5 mM) of each peptide
were used. The order of addition to each glass tube (600 µL) was (i) buffer, (ii) water, (iii)
fluorescent probe, and (iv) tripodal peptide. A background control (without the peptide) was
used. The fluorescence intensities of fluorescent probe interacting with the tripodal peptides
was calculated by the following equation:
where FPs is the fluorescent polarization value of the sample containing the peptide, and
FPbgd is the fluorescent polarization value of the background control (buffer + water + probe).
The fluorescence intensities of the various concentrations of the assayed peptides were plotted.
The reported values are the mean of three separate determinations with a standard deviation
of less than 5%.
4. Cellular Uptake Assay
4.1. Fluorescence Microscopy
4.1.1. Fluorescence Microscopy of F-LPA4 in BT-20 Cells (Figure 5) and Fluorescence
Microscopy of F-GpYEEI in the Presence of LPA4 in MDA-MB-468 Cells (Figure 6):
The cellular uptake studies and intracellular localization of F-LPA4 and LPA4 + F-GpYEEI
was imaged using fluorescence microscopy. The human breast carcinoma xenograft cells
[MDA-MB-468 (ATCC # HTB-132) or BT-20 (ATCC # HTB-19)] were grown on circular
glass coverslips in 6-well culture plates having modified Eagle’s medium (EMEM). Upon
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reaching about 70% confluency, they were washed once with serum-free media (SFM)
followed by incubation with a solution of F-LPA4 (or LPA4 + F-GpYEEI) (10 µM for each
solution in SFM prepared from stock solution in DMSO) in different periods (5, 10, 30 and 60
min). At the end of each incubation time-point, the cells were washed twice with phosphate
buffered saline (PBS, pH 7.4) and fixed using ice-cold primary cell fixative (1:1 mixture of
glutaraldehyde: formaldehyde, 4% aqueous solution). The cells were mounted on glass slides
with cell-side down using Fluormount medium and edges were sealed with a resin solution.
They were observed under fluorescent microscope under FITC channel (480/520 nm).
4.1.2. Real Time Fluorescence Microscopy in Live BT-20 Cells (Figure 7): The cellular
uptake studies and intracellular localization of LPA4 + F-GpYEEI were imaged using ZEISS
Axioplan 2 light microscope equipped with transmitted light microscopy with differential-
interference contrast method and an Achroplan 40X objective. The human breast carcinoma
cells BT-20 (ATCC # HTB-19) were grown on 25 cm2 cell culture flasks with Eagle’s
Minimum Essential Medium (EMEM) with 10% fetal bovine serum. Upon reaching about 70%
confluency, they were washed once with serum-free media (SFM) followed by incubation with
a solution of 10 µM of F-GpYEEI alone or with 50 µM of LPA1 or LPA4, and incubated for
30 min at 37 °C. They were then observed under fluorescent microscope under brightfield and
FITC channels (480/520 nm).
4.2. Semi-Quantitative Estimation of Cellular Uptake of LPA4—BT-20 cells were
seeded in 96-well plates at a density of 10,000 cells per well with EMEM. They were allowed
to adhere and grow for 24 hours. The medium was replaced with SFM and graded
concentrations (5, 10, 25, 50, 100 µM) of the LPA4 and incubated for 24 h. The cells were
washed twice with PBS (pH 7.4) and EMEM was added before measuring the fluorescent
intensity (480/520 nm) using a plate reader. Eight wells were used per concentration. The blank
was the group of cells that received only SFM. Percentage increase in fluorescent intensity was
calculated against the control.
4.3. Flow Cytometry
4.3.1. General Information: All of the stock peptide solutions were prepared in DMSO and
diluted 1000 times to make the final concentration before using. The human breast carcinoma
cells BT-20 (ATCC# HTB-19) were grown on 25 cm2 cell culture flasks with Eagle’s Minimum
Essential Medium (EMEM) with 10% fetal bovine serum. Upon reaching about 70%
confluency, the cells were treated as described below and incubated for 30 min at 37 °C. Then
they were washed twice with serum-free medium followed by treating with 0.25% trypsin/0.53
mM EDTA at 37 °C for 5 min and washed with 1 mL PBS (pH = 7.4) at 2500 rpm for 5 min.
The cells were then fixed in cold 75% ethanol for 30 min at −20°C followed by washing twice
with 1 mL PBS and spinning at 2500 rpm and the supernatant was carefully discarded to avoid
cell loss. Then the cells were analyzed by Flow Cytometry (FACSCalibur: Becton Dickinson)
using FITC channel and CellQuest software. The data presented are based on the mean
fluorescence signal for 5000 cells collected. All the assays were done in triplicate.
4.3.2. Cellular Uptake of F-GpYEEI or F-LPA-4 at Different Concentrations: Upon the
cells reaching about 70% confluency, the medium was replaced with 2 mL serum-free medium
and 2 µL of graded concentrations (0, 1.25, 2.5, 5, 10 and 20 mM in DMSO) of F-GpYEEI or
F-LPA-4. Then the assays were performed as described in General Information.
4.3.3. Cellular Uptake of F-LPA-4 with Sodium Azide: The assays were performed as
previously described in 4.3.2 with the exception that the cells used were preincubated for 30
min with 0.5% sodium azide (77 mM) in EMEM before the addition of F-LPA4. The uptake
assays were run in parallel in the presence and absence of sodium azide.
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4.3.4. Cellular Uptake Assay of F-GpYEEI and F-GYEEI in the Presence of LPA-1 and
LPA-4: Upon the cells reaching about 70% confluency, the medium was replaced with 2 mL
serum-free medium with DMSO as control and 10 µM of F-GpYEEI or F-GYEEI with 50 µM
of LPA-1 or LPA-4, and incubated for 30 min at 37 °C. Then the assays were performed as
described in General Information.
4.3.5. Cellular Uptake Assay of F-GpYEEI in the Presence of LPA-1 and LPA-4 and Salt
Ions: NaCl and KCl were prepared. The assays were performed as described in 4.3.2 with the
exception that salt ions solutions were used instead of EMEM.
4.3.6. Cellular Uptake Assay of F-GpYEEI in the Presence of LPA-4 in Sodium Hydrogen
Phosphate Solutions: Upon the cells reaching about 70% confluency, the medium was
replaced with 2 mL of different concentrations of sodium hydrogen phosphate (0 mg/L, 12.5
mg/L and 25 mg/L of Na2HPO4 in EMEM) and 10 µM F-GpYEEI with 50 µM of LPA-4. Then
the assays were performed as described in General Information.
5. Cell Viability Assay
Upon the cells reaching about 70% confluency, the medium was replaced with 2 mL serum-
free medium with DMSO as control, F-GpYEEI (10 µM), F-LPA-4 (10 µM), F-GpYEEI (10
µM) with LPA-1 (50 µM), or F-GpYEEI (10 µM) with LPA-4 (50 µM), and incubated for 30
min at 37 °C. Then the cells were treated with 0.25% trypsin/0.53 mM EDTA at 37 °C for 5
min. Both of the supernatant and the detached cells were collected and centrifuged at 2500 rpm
for 5 min. The cell pellets were then suspended in 1 mL serum-free medium and analyzed using
Vi-Cell Cell Viability Analyzer (Beckman Coulter) (triplicate assay).
6. Circular Dichroism (CD) Spectroscopy
All CD spectra were recorded in 1 cm path length cylindrical cells on a nitrogen-flushed JASCO
J-810 spectropolarimeter interfaced with a 25 °C water bath by averaging 3 consecutive scans.
All spectra were recorded with a 4 sec response and a band width of 1 nm. CD spectra were
measured with the spectropolarimeter using a 50 nm.min−1 scan speed. All spectra were
corrected for background by subtraction of appropriate blanks. The data are represented in the
190–260 nm spectral range.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Synthesized tripodal positively charged peptide analogues.
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Figure 2.
The FP binding assays of the peptide analogues in the presence of F-GpYEEI (80 nM).
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Figure 3.
The FP binding assay of LPA4 in the presence of F-GpYEEI (80 nM) or F-LPA4 (80 nM).
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Figure 4.
Selectivity of LPA8 and LPA4 toward the fluorescence-attached peptide probes (80 nM). F-
GpYEEI was used as a control.
Ye et al. Page 21
J Med Chem. Author manuscript; available in PMC 2008 September 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5.
The cellular uptake of F-LPA4 represented by fluorescence intensity in cytosol in BT-20 cells
(left); The fluorescence intensity and therefore the cellular uptake of F-LPA4 (5–100 µM) were
concentration-dependent (right).
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Figure 6.
Cellular uptake assay of LPA4 (10 µM) and F-GpYEEI (10 µM) using MDA-MB-468 cells.
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Figure 7.
Real time fluorescence microscopy of F-GpYEEI (10 µM) in the presence of LPA4 (50 µM)
or LPA1 (50 µM) using live BT-20 cells.
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Figure 8.
Cell viability assay of F-GpYEEI, F-LPA4, F-GpYEEI + LPA1 and F-GpYEEI + LPA4.
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Figure 9.
Concentration-dependent cellular uptake of F-LPA4 in the presence and absence of sodium
azide.
Ye et al. Page 26
J Med Chem. Author manuscript; available in PMC 2008 September 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 10.
FACS cellular uptake assay with F-GpYEEI vs. F-GYEEI (10 µM) in the presence and absence
of LPA-1 and LPA-4 (50 µM).
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Figure 11.
(a) CD spectropolarimetry of LPA4 in different concentrations: 1 (1 µM), 2 (5 µM), 3 (10 µM),
4 (25 µM), 5 (50 µM), 6 (100 µM); (b) CD spectropolarimetry of LPA4 (50 µM) in the presence
of different concentrations of F-GpYEEI: 1 (0 µM), 2 (1 µM), 3 (5 µM), 4 (10 µM), 5 (15 µM),
6 (20 µM).
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Figure 12.
Cellular uptake assay with F-GpYEEI (10 µM) in the presence of LPA4 (50 µM) in cell culture
medium vs. NaCl, KCl, and sodium hydrogen phosphate solutions.
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Figure 13.
Cellular uptake of 5'-fluorescence labeled d(TTTTTTTTTTTT) (10 µM) in the presence of
LPA-1 and LPA-4 (50 µM).
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Scheme 1.
Synthesis of CP.
Ye et al. Page 31
J Med Chem. Author manuscript; available in PMC 2008 September 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Scheme 2.
Synthesis of DPA.
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Scheme 3.
Fmoc peptide synthesis of LPA8.
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Scheme 4.
Synthesis of F-LPA4.
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